Brind.

New Spin-Out IMS Solutions Launches with £2.1M Research Grant

1 report, 1 independent Updated Sep 22
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Intelligent Mass Spec Solutions Ltd (IMS Solutions) has launched as a spin-out from the research of the University of Birmingham and Imperial College London. The company focuses on developing platforms to diagnose conditions involving disordered steroid hormone metabolism. IMS Solutions secured a £2.1 million research grant from the National Institute for Health and Care Research (NIHR) and also launched with a £1.1 million Seed round led by various investors, including SFC Capital and the British Business Bank.

From news-medical.net

Why it matters

Some supportBrind's analysis of the reports

The NIHR funding will enable IMS Solutions to refine a urine test for the early diagnosis of Adrenocortical Carcinoma (ACC) in the UK by 2029. The company is also working to develop a stratification test for Polyendocrine Metabolic Ovarian Syndrome (PMOS). This represents the commercialization of academic research into a deep-tech medical diagnostic product.

From news-medical.net

Who's involved

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • The company could secure future contracts for its diagnostic tests within the healthcare sector.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped